会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Antibodies that bind to the C35 polypeptide
    • 结合C35多肽的抗体
    • US07968688B2
    • 2011-06-28
    • US12350937
    • 2009-01-08
    • Maurice ZaudererElizabeth E. Evans
    • Maurice ZaudererElizabeth E. Evans
    • C12P21/08C07K16/00A61K39/395C12P21/04
    • C07K16/32A61K38/00C07K14/4748C07K2317/56C07K2319/00
    • The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
    • 本发明涉及在人癌中差异表达的新型人基因。 更具体地,本发明涉及编码在人乳腺癌和膀胱癌中过表达的名为C35的新型人多肽的多核苷酸。 本发明还涉及C35多肽,特别是C35肽表位和C35肽表位类似物,以及载体,宿主细胞,针对C35多肽的抗体及其制备方法。 本发明还涉及用于检测癌症的诊断方法,包括人乳腺癌。 本发明还涉及在免疫原性组合物或疫苗中C35基因和多肽,特别是C35肽表位和C35肽表位类似物的配制和用途,以诱导针对靶细胞例如肿瘤细胞的抗体或细胞介导的免疫 ,表达C35基因。 本发明还涉及鉴定C35活性的激动剂和拮抗剂的筛选方法。
    • 6. 发明授权
    • Methods for producing polynucleotide libraries in vaccinia virus
    • 用于在痘苗病毒中产生多核苷酸文库的方法
    • US06706477B2
    • 2004-03-16
    • US09822250
    • 2001-04-02
    • Maurice Zauderer
    • Maurice Zauderer
    • C12Q168
    • C12N15/1086C12N15/1034
    • The present invention relates to novel methods for the identification of antigens recognized by cytotoxic T cells (CTLs) and specific for human tumors, cancers, and infected cells, and the use of such antigens in immunogenic compositions or vaccines to induce regression of tumors, cancers, or infections in mammals, including humans. The invention encompasses methods for induction and isolation of cytotoxic T cells specific for human tumors, cancers and infected cells, and for improved selection of genes that encode the target antigens recognized by these specific T cells. The invention also relates to differential display methods that improve resolution of, and that reduce the frequency of false positives of DNA fragments that are differentially expressed in tumorous, cancerous, or infected tissues versus normal tissues. The invention further relates to the engineering of recombinant viruses as expression vectors for tumor, cancer, or infected cell-specific antigens.
    • 本发明涉及用于鉴定由细胞毒性T细胞(CTL)识别并且对人肿瘤,癌症和感染细胞特异性的抗原的新方法,以及在免疫原性组合物或疫苗中使用这些抗原诱导肿瘤,癌症消退 ,或哺乳动物,包括人类的感染。 本发明包括用于诱导和分离对人肿瘤,癌症和感染细胞特异性的细胞毒性T细胞的方法,以及改进编码由这些特异性T细胞识别的靶抗原的基因的选择。 本发明还涉及差异显示方法,其提高在肿瘤,癌性或感染组织中与正常组织差异表达的DNA片段的分离度并降低其误差的频率。 本发明还涉及重组病毒作为肿瘤,癌症或感染的细胞特异性抗原的表达载体的工程。
    • 8. 发明授权
    • Polynucleotides encoding antibodies that bind to the C35 polypeptide
    • 编码结合C35多肽的抗体的多核苷酸
    • US07563882B2
    • 2009-07-21
    • US10457829
    • 2003-06-10
    • Maurice ZaudererElizabeth E. Evans
    • Maurice ZaudererElizabeth E. Evans
    • C07H21/04C12P21/04C12N15/00A61K39/395C12P21/08C07K16/00
    • C07K16/32A61K38/00C07K14/4748C07K2317/56C07K2319/00
    • The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
    • 本发明涉及在人癌中差异表达的新型人基因。 更具体地,本发明涉及编码在人乳腺癌和膀胱癌中过表达的名为C35的新型人多肽的多核苷酸。 本发明还涉及C35多肽,特别是C35肽表位和C35肽表位类似物,以及载体,宿主细胞,针对C35多肽的抗体及其制备方法。 本发明还涉及用于检测癌症的诊断方法,包括人乳腺癌。 本发明还涉及在免疫原性组合物或疫苗中C35基因和多肽,特别是C35肽表位和C35肽表位类似物的配制和用途,以诱导针对靶细胞例如肿瘤细胞的抗体或细胞介导的免疫 ,表达C35基因。 本发明还涉及鉴定C35活性的激动剂和拮抗剂的筛选方法。
    • 10. 发明授权
    • Methods of selecting polynucleotides encoding antigens
    • 选择编码抗原的多核苷酸的方法
    • US06800442B2
    • 2004-10-05
    • US10034350
    • 2002-01-03
    • Maurice Zauderer
    • Maurice Zauderer
    • C12Q168
    • C12N15/1086C12N15/1034
    • The present invention relates to novel methods for the identification of antigens recognized by cytotoxic T cells (CTLs) and specific for human tumors, cancers, and infected cells, and the use of such antigens in immunogenic compositions or vaccines to induce regression of tumors, cancers, or infections in mammals, including humans. The invention encompasses methods for induction and isolation of cytotoxic T cells specific for human tumors, cancers and infected cells, and for improved selection of genes that encode the target antigens recognized by these specific T cells. The invention also relates to differential display methods that improve resolution of, and that reduce the frequency of false positives of DNA fragments that are differentially expressed in tumorous, cancerous, or infected tissues versus normal tissues. The invention further relates to the engineering of recombinant viruses as expression vectors for tumor, cancer, or infected cell-specific antigens.
    • 本发明涉及用于鉴定由细胞毒性T细胞(CTL)识别并且对人肿瘤,癌症和感染细胞特异性的抗原的新方法,以及在免疫原性组合物或疫苗中使用这些抗原诱导肿瘤,癌症消退 ,或哺乳动物,包括人类的感染。 本发明包括用于诱导和分离对人肿瘤,癌症和感染细胞特异性的细胞毒性T细胞的方法,以及改进编码由这些特异性T细胞识别的靶抗原的基因的选择。 本发明还涉及差异显示方法,其提高在肿瘤,癌性或感染组织中与正常组织差异表达的DNA片段的分离度并降低其误差的频率。 本发明还涉及重组病毒作为肿瘤,癌症或感染的细胞特异性抗原的表达载体的工程。